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T cell checkpoint-targeted cancer immunotherapies are making an increasing impact on clinical practice, 
and their investigation in clinical trials has risen exponentially[1]. Effective and efficient response 
evaluation is essential, but represents challenges due to idiosyncratic radiological responses and lack of 
early response biomarkers. Concerted efforts to overcome these challenges have included the generation 
of immune-related response criteria (irRC)[2, 3] to better accommodate immunotherapy associated 
response kinetics, and recommendations for immunological monitoring throughout all phases of clinical 
trial design to help identify predictive/ prognostic biomarkers of response and mechanistic insight into 
patterns of resistance[3, 4]. 
We assessed quantitatively the inclusion of irRC and immunological biomarker primary response 
monitoring in the registration details of T cell checkpoint-targeted cancer immunotherapy trials in solid 
malignancies registered on the U.S. National Institutes of Health (NIH) trial registry (clinicaltrials.gov) by 
7th October 2016. To overcome potential limitations from incomplete registrations, data were analyzed 
across three consecutive five year periods. 
During the completed years, 2001-2015, 91% (622/685) of immunotherapy trials registered use of a 
radiological endpoint. Analyzing the trend of utilization, we found a significantly increasing (p=0.014) 
proportion of these trials specified use of the WHO/RECIST, reaching 56% (307/551) in the last five 
years. Use of the irRC (established in 2009) also increased, but only reached 25% (135/551) of trials. A 
total of 38% (234/622) of trials registered use of an imaging endpoint without specifying imaging criteria. 
Overall, only 38% (259/685) of trials included immunological biomarker monitoring, and this proportion 
decreased significantly (p=0.011) over three consecutive five year periods. 
These findings highlight three areas of concern. Firstly, underutilization of the irRC may be associated 
with an underestimation of treatment response[2, 5]. This impact may be dependent on tumor type [6] or 
checkpoint-targeted agent [7] dependent. However, prospective inclusion of radiological criteria that 
accommodate unconventional response kinetics is essential in order to avoid misclassification of response 
and inappropriate cessation of effective therapy. Secondly, the failure to incorporate immunological, and 
emerging host-centric[8], biomarker monitoring presents a missed opportunity to establish surrogate 
markers of response and/ or resistance[3, 4]. Thirdly, specification and/or metrics of imaging outcome 
measures were found wanting in 234 trials, an omission which should be addressed, particularly in view 
of recent regulations[9]. 
The underutilization of recommended radiographic and immunological monitoring identified by these 
data, together with sub-optimal dose finding identified by others[10], may limit the interpretation of 
clinical trial results and thereby the development of effective cancer immunotherapies and consensus 
guidelines for their use. Increasing the incorporation of these measures will help answer the call for 
greater accountability in the design of clinical trials to optimize the value of data generated[4, 9]. This 
will improve our knowledge, and application, of immunotherapy for the benefit of patients with cancer. 
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 Radiological and Immune Biomarker Monitoring in T cell Checkpoint-Targeted Cancer 
Immunotherapy Trials.  All 685 T cell checkpoint-targeted cancer immunotherapy trials registered on 
the U.S. NIH trial registry between 2001 and 2015 were categorized according to year of registration and 
registered imaging and immune biomarker outcome measures (left) and radiological response criteria 
(right). Six trials used the RANO criteria (not shown). Immune biomarkers included monitoring of any 
immune related parameter, including via immunohistochemistry, immune cell counts, cytokine analysis 
and humoral/ cellular immune responses. Univariate analysis for data presented was performed using the 
Cochran-Armitage test for trend. *p<0.05; ***p<0.001. 
 
 
